Citation Impact
Citing Papers
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Point-of-Care Testing
2012 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Systematic review of outpatient services for chronic pain control.
1997
Assays of different aspects of haemostasis – what do they measure?
2015 StandoutNobel
Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study
2009 StandoutNobel
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX
2003
Cancer burden in the year 2000. The global picture
2001 Standout
The Effect of Recombinant Factor VIIa on Coagulopathic Pigs with Grade V Liver Injuries
2002
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel
2015 StandoutNobel
Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature
2008
Descending control of pain
2002 Standout
The Emerging Role of Recombinant-Activated Factor VII in Neurocritical Care
2004
New Antithrombotic Drugs
2012
A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery
2008
Long Noncoding RNAs in Cancer Pathways
2016 Standout
Treating coagulopathy in trauma patients
2003
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial
2003
Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience
2007
Increased Plasma and Platelet to Red Blood Cell Ratios Improves Outcome in 466 Massively Transfused Civilian Trauma Patients
2008 Standout
The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet Disorders
2007
Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma
2001
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
2005 Standout
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
2006 Standout
Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events
2002
Portal hypertensive bleeding in cirrhosis
2016 Standout
Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function
2006
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
2014
Immune Thrombocytopenic Purpura
2002 Standout
The Ratio of Blood Products Transfused Affects Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital
2007 Standout
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review
2005
Early Coagulopathy Predicts Mortality in Trauma
2003 Standout
Platelets in inflammation and atherogenesis
2005 Standout
Treating Traumatic Bleeding in a Combat Setting: Possible Role of Recombinant Activated Factor VII
2004
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial
2004
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Dosing with recombinant factor viia based on current evidence
2004
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
2015
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Current Options in Platelet Function Testing
2006
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Global cancer statistics in the year 2000
2001 Standout
Measuring antiplatelet drug effects in the laboratory
2007
The Evolution of Consciousness as a Planetary Imperative: An Integration of Integral Views
2007 Standout
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
2011 Standout
Antagonism of the Melanocortin System Reduces Cold and Mechanical Allodynia in Mononeuropathic Rats
2000
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
2016
Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor–independent thrombin generation
2003
Recombinant Factor VIIa for Bleeding in Refractory Thrombocytopenia
2000
Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery
1998
Platelets and Cardiovascular Disease
2002
Chapter 4European guidelinesfor the management of chronicnonspecific low back pain
2006 Standout
Arginine Carboxypeptidase (CPR) in Human Plasma Determined with Sandwich ELISA
1999 StandoutNobel
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Glycoprotein IIb/IIIa Inhibitors: An Update on the Mechanism of Action and use of Functional Testing Methods to Assess Antiplatelet Efficacy
2011
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
2011
Guidelines for the management of hemophilia
2012 Standout
Hematological Problems in Pediatric Intensive Care
2013 Standout
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
1996
Works of Steven Glazer being referenced
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement
2013
Experience With Recombinant Factor VIIA in an Infant Hemophiliac With Inhibitors to FVIILC Undergoing Emergency Central Line Placement
1993
Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders
1993
Clinical Experience with Recombinant Factor VIla in Patients with Thrombocytopenia
1996
Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects
2011
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention
2001
Clinical update on the use of recombinant factor VII
1995
Tolerability and pharmacokinetics of TB-402 in healthy male volunteers
2010
Management of Hemophilia Patients with Inhibitors
1992
Immunological Aspects of Recombinant Factor Vila (rFVIIa) in Clinical Use
1996
Abstract A111: A phase I, dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with solid tumors
2009
The heart of learning : spirituality in education
1999
Systemic local anesthetics in pain control
1991